Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Invex Therapeutics.
RELATED STOCKHEAD STORIES
Health & Biotech
Chimeric IPO: What ASX stockspert Bhavdip143 likes so much about the $35m CAR T play
News
Rise and Shine: What you need to know before the ASX opens
News
Rise and Shine: What you need to know before the ASX opens
News
Small caps were still raising money in May; health beat resources again
News
Rise and Shine: What you need to know before the ASX opens
News
Rise and Shine: What you need to know before the ASX opens
Health & Biotech
Dr Boreham’s Crucible: Why Invex has all the right ingredients to possibly become a takeover target
News
Rise and Shine: What you need to know before the ASX opens
Escrow Watch
Escrow Watch: Watch out for these bundles of stock about to land on the ASX
Health & Biotech
WA biotechs are booming; now government wants to make the state a life sciences hub
Health & Biotech
Biotech: GMV finishes trials needed to enter Chinese market; shares rally
Health & Biotech
Biotech: Invex hopes to blow minds with hypertension drug results
IPO Watch
IPO Watch: These are the top ASX debutantes of 2019
Health & Biotech
Health Kick Podcast: Investing in repurposed drugs, combating intracranial pressure and why Invex caught NASA’s eye
Health & Biotech
The science behind Invex Therapeutics could be used to help astronauts get to Mars
Health & Biotech
Health: Immutep gains 12% on promising melanoma treatment
IPO Watch
